This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.
The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.
Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.
So the question, as narrowly as I can put it: which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Tell me what I have not thought of.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
NeuroNate said:The mechanism is more central than most summaries suggest.
Agreed, and the early-responder data is relevant to expectations: roughly 3% loss by week four at a therapeutic dose predicts a strong result at a year. It does not mean someone below that will not respond, but it changes how long you should wait before changing something.
NeuroNate said:The mechanism is more central than most summaries suggest.
Pushing back on NeuroNate here. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAnswering the narrow version, because the broad one does not have a single answer. Genuine plateaus happen too, and the mechanism is metabolic adaptation plus a smaller body. A body 20kg lighter needs meaningfully fewer calories at rest and less to move, so the deficit that produced the first phase is arithmetically smaller now. The options are the honest ones — increase the deficit slightly, increase activity, or accept the new plateau — and escalating the dose is only one of them.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Dr.ObesityMed said:Agreed, and the early-responder data is relevant to expectations: roughly 3% loss by week four at a therapeutic dose predicts a strong result at a…
This matches mine closely enough to be worth saying so out loud. I had assumed I was the exception until I read this.